|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0018956,
umls-concept:C0030705,
umls-concept:C0185112,
umls-concept:C0205195,
umls-concept:C0278488,
umls-concept:C0392920,
umls-concept:C0393029,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2698651,
umls-concept:C2911692
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2000-1-11
|
|
pubmed:abstractText |
Based on our preliminary experience, we have further evaluated the capacity of the paclitaxel/epirubicin combination (at the dose of 175 and 90 mg/m(2), respectively) plus G-CSF to mobilize hematopoietic progenitors into the circulation.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
pubmed-author:Da PradaG AGA,
pubmed-author:GibelliNN,
pubmed-author:LanzaAA,
pubmed-author:PedrazzoliPP,
pubmed-author:PerottiCC,
pubmed-author:PonchioLL,
pubmed-author:Robustelli della CunaGG,
pubmed-author:SalvaneschiLL,
pubmed-author:TorrettiDD,
pubmed-author:ZambelliAA,
pubmed-author:ZiberaCC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
84
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
924-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10509041-Adult,
pubmed-meshheading:10509041-Antigens, CD34,
pubmed-meshheading:10509041-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10509041-Breast Neoplasms,
pubmed-meshheading:10509041-Clone Cells,
pubmed-meshheading:10509041-Combined Modality Therapy,
pubmed-meshheading:10509041-Epirubicin,
pubmed-meshheading:10509041-Female,
pubmed-meshheading:10509041-Graft Survival,
pubmed-meshheading:10509041-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:10509041-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:10509041-Humans,
pubmed-meshheading:10509041-Leukapheresis,
pubmed-meshheading:10509041-Middle Aged,
pubmed-meshheading:10509041-Paclitaxel,
pubmed-meshheading:10509041-Prospective Studies,
pubmed-meshheading:10509041-Time Factors,
pubmed-meshheading:10509041-Transplantation, Autologous
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Efficacy of epirubicin/paclitaxel combination in mobilizing large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen.
|
|
pubmed:affiliation |
Divisione di Oncologia Medica, Fondazione "S. Maugeri", via Ferrata 8, 27100 Pavia, Italy. czibera@fsm.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
